📰 Alvr News
Page 2 - Alvr News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alvr. Real-time updates on events, politics, business and more.
December 22, 2023
By Will Feuer AlloVir, a clinical-stage cell-therapy company, said it has halted three of its late-stage clinical trials following recommendations from...
December 22, 2023
Shares of AlloVir Inc. plummeted 66.6% toward their first-ever close below $1 on heavy volume in afternoon trading Friday, after the immunotherapy company...
November 28, 2023
AlloVir (NASDAQ:ALVR – Get Free Report) and Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends. Insider & Institutional Ownership 47.4% of AlloVir shares […]
November 24, 2023
AlloVir (NASDAQ:ALVR – Get Free Report) and Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends. Earnings and Valuation This table compares AlloVir and […]
October 31, 2023
AlloVir (NASDAQ:ALVR – Get Free Report) will be announcing its earnings results on Wednesday, November 1st. AlloVir (NASDAQ:ALVR – Get Free Report) last released its earnings results on Thursday, August 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.03). On average, analysts expect AlloVir to […]
August 21, 2023
Bank of America assumed coverage on shares of AlloVir (NASDAQ:ALVR – Free Report) in a report published on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $17.00 target price on the stock. Other equities analysts have also issued reports about the company. SVB Securities upped their target price on AlloVir from $16.00 […]
August 18, 2023
Equities researchers at Bank of America began coverage on shares of AlloVir (NASDAQ:ALVR – Get Free Report) in a note issued to investors on Friday, FlyOnTheWall reports. The brokerage set a “buy” rating on the stock. Several other brokerages have also weighed in on ALVR. Morgan Stanley restated an “overweight” rating and issued a $20.00 […]
August 18, 2023
By Dean Seal Shares of AlloVir are climbing after Bank of America initiated coverage of the company with a buy rating, citing its innovative platform and the...
August 9, 2023
Morgan Stanley restated their overweight rating on shares of AlloVir (NASDAQ:ALVR – Free Report) in a report released on Monday, Benzinga reports. Morgan Stanley currently has a $20.00 price target on the stock. Separately, SVB Securities raised their price target on shares of AlloVir from $16.00 to $19.00 in a research report on Wednesday, April […]
August 1, 2023
AlloVir (NASDAQ:ALVR – Get Free Report) is set to post its quarterly earnings results on Wednesday, August 2nd. AlloVir (NASDAQ:ALVR – Get Free Report) last released its quarterly earnings results on Thursday, May 4th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03. On average, analysts expect AlloVir […]